Inflammation's Role in Protein Effectiveness for Muscle Building in Cancer Patients
Recent research has shed light on the complex relationship between protein intake and muscle building, particularly in individuals with colorectal cancer undergoing chemotherapy. The study, part of the PRIMe trial, aimed to determine whether increasing protein intake could help patients maintain muscle mass during treatment. Participants received tailored nutrition counseling to achieve protein intakes of either 1.0 or 2.0 grams per kilogram of body weight per day over a 12-week period.
In this follow-up analysis, researchers evaluated data from 50 participants, averaging 57 years old, tracking their protein intake and lean soft tissue, which includes muscle, through DEXA scans. Blood samples collected at the beginning of the study and at six and twelve weeks were analyzed for inflammation markers, hormones, and amino acids. While participants did increase their protein intake, the muscle-building response varied significantly among individuals. A key finding was the role of IL-6, a protein involved in the body's inflammatory response. Participants with higher baseline IL-6 levels exhibited smaller improvements in lean soft tissue despite increased protein consumption.
The study also revealed that the amount of additional protein consumed was crucial. Those who increased their daily intake by at least 27 grams—approximately equivalent to a scoop of protein powder or a protein-rich snack—showed measurable improvements in lean soft tissue by the six-week mark. Furthermore, baseline levels of IL-6, insulin, certain amino acids, and changes in protein intake accounted for 77% of the variation in muscle response observed at six weeks. Notably, factors such as cancer stage and chemotherapy type did not appear to influence the differences in muscle response.
Understanding the mechanics of protein utilization is vital. Protein serves as the raw material for muscle repair and growth, broken down into amino acids that stimulate muscle protein synthesis. However, inflammation can hinder this process, leading to what researchers term "anabolic resistance." This condition means that the muscle does not respond as effectively to protein intake, which could explain why two individuals consuming similar protein amounts might experience different results.
It's important to note that this research specifically involved individuals with colorectal cancer, leaving open questions about whether similar patterns apply to healthy adults or other populations. The findings do not suggest that everyone should increase their protein intake or attempt to lower inflammation based solely on IL-6 levels. Maintaining adequate protein intake and engaging in resistance training remain essential for muscle health. However, for those struggling to build or maintain muscle despite sufficient protein and exercise, especially with underlying health conditions, consulting a healthcare professional is advisable.
This research underscores that muscle health is not solely about achieving a specific protein target; the body's ability to effectively utilize that protein is equally important. In patients with colorectal cancer, elevated IL-6 levels were linked to diminished muscle gains following increased protein intake, highlighting inflammation's potential impact on protein effectiveness.




